利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.024 秒)

    Serotonin and norepinephrine reuptake inhibitors and uses thereof
    1.
    发明申请
    Serotonin and norepinephrine reuptake inhibitors and uses thereof 失效
    5-羟色胺和去甲肾上腺素再摄取抑制剂及其用途

    公开(公告)号：US20070015791A1

    公开(公告)日：2007-01-18

    申请号：US11485693

    申请日：2006-07-13

    申请人： Syed Shah ,  Mahdi Fawzi ,  Panolil Raveendranath ,  Eric Ehrnsperger

    发明人： Syed Shah ,  Mahdi Fawzi ,  Panolil Raveendranath ,  Eric Ehrnsperger

    IPC分类号： A61K31/445 ,  C07D211/44

    CPC分类号： C07D211/44

    摘要： Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

    摘要翻译： 提供选择性双重5-羟色胺和去甲肾上腺素再摄取抑制剂。 这些化合物具有较低的副作用特征，并且可用于治疗各种病症的组合物和产品，包括抑郁症，纤维肌痛，焦虑症，惊恐障碍，广泛性恐惧症，创伤后应激障碍，经前焦虑障碍，注意力缺陷障碍， 强迫症，社会焦虑症，广泛性焦虑症，自闭症，精神分裂症，肥胖症，神经性厌食症，神经性贪食症，杜氏综合征，血管舒缩性潮红，可卡因和酒精成瘾，性功能障碍，边缘性人格障碍，纤维肌痛综合征，糖尿病性神经病变 疼痛，慢性疲劳综合征，疼痛，Shie Drager综合征，雷诺综合征，帕金森病和癫痫。

    Serotonin and norepinephrine reuptake inhibitor and uses thereof
    2.
    发明申请
    Serotonin and norepinephrine reuptake inhibitor and uses thereof 失效
    5-羟色胺和去甲肾上腺素再摄取抑制剂及其应用

    公开(公告)号：US20070015824A1

    公开(公告)日：2007-01-18

    申请号：US11486336

    申请日：2006-07-13

    申请人： Syed Shah ,  Mahdi Fawzi ,  Eric Ehrnsperger ,  Panolil Raveendranath

    发明人： Syed Shah ,  Mahdi Fawzi ,  Eric Ehrnsperger ,  Panolil Raveendranath

    IPC分类号： A61K31/35 ,  C07D309/10 ,  A61K9/48 ,  A61K9/20

    CPC分类号： C07D309/10 ,  A61K9/20 ,  A61K9/48

    摘要： Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

    摘要翻译： 提供选择性双重5-羟色胺和去甲肾上腺素再摄取抑制剂。 这些化合物具有较低的副作用特征，并且可用于治疗各种病症的组合物和产品，包括抑郁症，纤维肌痛，焦虑症，惊恐障碍，广场恐怖症，创伤后应激障碍，经前期焦虑障碍，注意力缺陷障碍， 强迫症，社会焦虑症，广泛性焦虑症，自闭症，精神分裂症，肥胖症，神经性厌食症，神经性贪食症，杜氏综合征，血管舒缩性潮红，可卡因和酒精成瘾，性功能障碍，边缘性人格障碍，纤维肌痛综合征，糖尿病性神经病变 疼痛，慢性疲劳综合征，疼痛，Shie Drager综合征，雷诺综合征，帕金森病和癫痫。

    Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
    3.
    发明申请
    Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof 审中-公开
    高选择性5-羟色胺和去甲肾上腺素双重摄取抑制剂及其用途

    公开(公告)号：US20070015828A1

    公开(公告)日：2007-01-18

    申请号：US11485663

    申请日：2006-07-13

    申请人： Syed Shah ,  Eric Ehrnsperger ,  Richard Saunders ,  Mahdi Fawzi ,  Rocco Galante ,  Garth Whiteside

    发明人： Syed Shah ,  Eric Ehrnsperger ,  Richard Saunders ,  Mahdi Fawzi ,  Rocco Galante ,  Garth Whiteside

    IPC分类号： A61K31/277 ,  A61K31/137

    CPC分类号： C07C215/64 ,  C07B2200/13 ,  C07C217/52 ,  C07C2601/14

    摘要： Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

    摘要翻译： 提供了高选择性双重5-羟色胺和去甲肾上腺素再摄取抑制剂。 这些化合物具有较低的副作用特征，并且可用于治疗各种病症的组合物和产品，包括抑郁症，纤维肌痛，焦虑症，惊恐障碍，广泛性恐惧症，创伤后应激障碍，经前焦虑障碍，注意力缺陷障碍， 强迫症，社会焦虑症，广泛性焦虑症，自闭症，精神分裂症，肥胖症，神经性厌食症，神经性贪食症，杜氏综合征，血管舒缩性潮红，可卡因和酒精成瘾，性功能障碍，边缘性人格障碍，纤维肌痛综合征，糖尿病性神经病变 疼痛，慢性疲劳综合征，疼痛，内脏痛，Shie Drager综合征，雷诺综合征，帕金森病和癫痫。

    Solid dosage formulations
    8.
    发明申请
    Solid dosage formulations 审中-公开
    固体剂型

    公开(公告)号：US20070259041A1

    公开(公告)日：2007-11-08

    申请号：US11799870

    申请日：2007-05-03

    申请人： Christopher Richard Diorio ,  Eric Ehrnsperger ,  Syed M. Shah

    发明人： Christopher Richard Diorio ,  Eric Ehrnsperger ,  Syed M. Shah

    IPC分类号： A61K31/137 ,  A61K9/24

    CPC分类号： A61K31/277 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/137

    摘要： Solid dosage formulations are provided for a compound having the formula: wherein R2 is Cl, F, Br, CH3, CF3, SCH3, NHCH3, NO2, CN, OH, OC1—C6 alkyl, or substituted OC1—C6 alkyl, or a prodrug or a pharmaceutically acceptable salt thereof. Formulations for tablets and multiparticulates containing a compound according to the above formula, a rate controlling component, and a binder are described, including formulations containing a seal coating, release rate controlling coating, and/or enteric coating. Pharmaceutical uses and kits thereof are also described.

    摘要翻译： 提供了具有下式的化合物的固体剂型：其中R 2是Cl，F，Br，CH 3，CF 3，SCH NH 3，NH 2，NO 2，CN，OH，OC 1 -C 6， 或其取代的OC 1 -C 6烷基，或其前药或药学上可接受的盐。 描述了包含根据上式的化合物，速率控制组分和粘合剂的片剂和多颗粒的制剂，包括含有密封涂层，释放速率控制涂层和/或肠溶衣的制剂。 还描述了药物用途及其试剂盒。